Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | PPM1B | O75688 | 1/20 | 0.47 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.47 |
| ▸ | PPP1CC | P36873 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.46 |
| ▸ | LMNA | P02545 | 3/20 | 0.45 |
| ▸ | CTSL | P07711 | 2/20 | 0.45 |
| ▸ | CAPN1 | P07384 | 2/20 | 0.45 |
| ▸ | CTSB | P07858 | 1/20 | 0.45 |
| ▸ | CTSG | P08311 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | MGAM | O43451 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | SI | P14410 | 1/20 | 0.42 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.42 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.42 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2387697 | 1.00 | TSHR (0.55) | TSHRPPM1BPTPN1PPP1CCALDH1A1 | |
| SCHEMBL2387688 | 1.00 | TSHR (0.55) | TSHRPPM1BPTPN1PPP1CCALDH1A1 | |
| SCHEMBL5317413 | 1.00 | TSHR (0.55) | TSHRPPM1BPTPN1PPP1CCALDH1A1 | |
| SCHEMBL11545787 | 1.00 | TSHR (0.55) | TSHRPPM1BPTPN1PPP1CCALDH1A1 | |
| SCHEMBL5556039 | 0.97 | TSHR (0.53) | TSHRPPM1BPTPN1PPP1CCALDH1A1 | |
| SCHEMBL12831369 | 0.91 | TSHR (0.49) | TSHRPPM1BPTPN1PPP1CCALDH1A1 | |
| SCHEMBL12635439 | 0.91 | TSHR (0.49) | TSHRPPM1BPTPN1PPP1CCALDH1A1 | |
| SCHEMBL29234725 | 0.91 | TSHR (0.53) | TSHRPPM1BPTPN1PPP1CCALDH1A1 | |
| SCHEMBL1238213 | 0.91 | TSHR (0.53) | TSHRPPM1BPTPN1PPP1CCALDH1A1 | |
| SCHEMBL1806931 | 0.91 | TSHR (0.53) | TSHRPPM1BPTPN1PPP1CCALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116082155-B | Method for preparing pinoxaden intermediate by using symmetrical epoxy compound | 上海工程技术大学 | 2024-07-16 | — | — | CN | disclosed |
| US-20240002396-A1 | MACROCYCLIC COMPOUNDS AND METHODS OF TREATMENT | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2024-01-04 | — | — | US | disclosed |
| CN-116082155-A | Method for preparing pinoxaden intermediate by using symmetrical epoxy compound | 上海工程技术大学 | 2023-05-09 | — | — | CN | disclosed |
| WO-2022076563-A1 | MACROCYCLIC COMPOUNDS AND METHODS OF TREATMENT | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2022-04-14 | — | — | WO | disclosed |
| EP-2811999-B1 | NOVEL CYSTEINE PROTEASE INHIBITORS AND USES THEREOF | UNIV COLUMBIA (US) | 2021-10-27 | — | — | EP | disclosed |
| US-10647709-B2 | Cysteine protease inhibitors and uses thereof | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2020-05-12 | — | — | US | disclosed |
| EP-3006432-B1 | 2,3-BUTANEDIAMIDE EPOXIDE COMPOUND AND PREPARATION METHOD AND USE THEREOF | INST PHARMACOLOGY & TOXICOLOGY ACAD MILITARY MEDICAL SCIENCES PLA CHINA (CN) | 2017-11-15 | — | — | EP | disclosed |
| US-9630957-B2 | 2,3-butanediamide epoxide compound and preparation method and use thereof | INSTITUTE OF PHARMACOLOGY AND TOXICOLOGY ACADEMY OF MILITARY MEDICAL SCIENCES P.L.A. CHINA (CN) | 2017-04-25 | — | — | US | disclosed |
| US-20170008884-A1 | NOVEL CYSTEINE PROTEASE INHIBITORS AND USES THEREOF | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK | 2017-01-12 | — | — | US | disclosed |
| US-20170008884-A1 | NOVEL CYSTEINE PROTEASE INHIBITORS AND USES THEREOF | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK | 2017-01-12 | — | — | US | disclosed |
| WO-2013116663-A1 | NOVEL CYSTEINE PROTEASE INHIBITORS AND USES THEREOF | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2013-08-08 | — | — | WO | disclosed |
| US-8013014-B2 | Aza-peptide epoxides | GEORGIA TECH RESEARCH CORPORATION (US) | 2011-09-06 | — | — | US | disclosed |
| US-8013014-B2 | Aza-peptide epoxides | GEORGIA TECH RESEARCH CORPORATION (US) | 2011-09-06 | — | — | US | disclosed |
| US-20080227806-A1 | Novel Drugs for Dementia | AMERICAN LIFE SCIENCE PHARMACEUTICALS (US) | 2008-09-18 | — | — | US | disclosed |
| WO-2007087572-A2 | AZA-PEPTIDE EPOXIDES | GEORGIA TECH RESEARCH CORPORATION (US) | 2007-08-02 | — | — | WO | disclosed |
| US-20060172952-A1 | Aza-peptide epoxides | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2006-08-03 | — | — | US | disclosed |
| US-7056947-B2 | For inhibiting (cysteine) proteases/caspases; for treatment of viral infections, stroke, neurodegenerative disease, and inflammatory diseases | GEORGIA TECH RESEARCH CORP. (US) | 2006-06-06 | — | — | US | disclosed |
| US-20040048327-A1 | Aza-peptide epoxides | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2004-03-11 | — | — | US | disclosed |
| WO-2004005270-A1 | AZA-PEPTIDE EPOXIDES | GEORGIA TECH RESEARCH CORPORATION (US) | 2004-01-15 | — | — | WO | disclosed |
| US-4393228-A | THIOL PROTEASE INHIBITORS, ANTIINFLAMMATORY | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 1983-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080227806-A1 | Novel Drugs for Dementia | CTSS, PRSS1, CBS | TSHR 4212/4885PPM1B 3374/4885PTPN1 3903/4885 |
| US-20240002396-A1 | MACROCYCLIC COMPOUNDS AND METHODS OF TREATMENT | MKI67, CCNC, PCNA | TSHR 1400/4885PPM1B 1134/4885PTPN1 2810/4885 |
| US-20170008884-A1 | NOVEL CYSTEINE PROTEASE INHIBITORS AND USES THEREOF | CAPNS1, CAPN9, CAPN1 | TSHR 4818/4885PPM1B 1879/4885PTPN1 2873/4885 |
| US-20060172952-A1 | Aza-peptide epoxides | CAPN9, CAPNS1, IAPP | TSHR 4233/4885PPM1B 1371/4885PTPN1 3823/4885 |
| US-10647709-B2 | Cysteine protease inhibitors and uses thereof | CAPNS1, CAPN9, CAPN1 | TSHR 4771/4885PPM1B 1782/4885PTPN1 2433/4885 |
| US-20040048327-A1 | Aza-peptide epoxides | ANPEP, ENPEP, TMPRSS15 | TSHR 4503/4885PPM1B 1421/4885PTPN1 1052/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.